Whether you are lyophilising or air drying your assay, your ultimate goal is to stabilise it for transport and storage at ambient temperature without loss of functional performance. Get expert advice on freeze drying and air drying Both processes involve the removal of water to achieve this and enable you to: eliminate the need for cold chain storage extend shelf
Developing a new assay that will ultimately find commercial success is notoriously complex. To that effect, managing your manufacturing processes in-house may initially appear to be the most streamlined and snag-free route to market. After all, what could benefit your production cycle more than having everything under one roof, ready for immediate analysis, testing and shipping? In reality,
We are proud to support the UICC’s World Cancer Day initiative
We are delighted to share the news that we have been shortlisted for the 2020 BioNow awards.
Biofortuna sees record production levels across November and December
Biofortuna has provided assay development and manufacturing support to QuantuMDx Group Limited to assist in the manufacturing scale-up, regulatory approval and launch of their rapid, sensitive SARS-CoV-2 test.
In light of the current situation with COVID-19, we would like to take this opportunity to assure you that plans have been put into place to ensure business continuity at Biofortuna.
Having developed over 100 assays across a range of diverse applications, let Biofortuna be your outsourcing partner of choice. Our FDA registered and ISO 13485 certified manufacturing facilities allow us to take your project from concept through to full commercial production and to market. Contact us now to discuss your requirements.
Biofortuna (Liverpool, UK) – the international IVD contract research and contract manufacturing company – will be launching ampDRY™, its patent pending stabilised master mix for PCR applications, at the AACC Annual Scientific Meeting and Clinical Lab Expo in Chicago, July 29 to August 2. ampDRY hotstart master mix has been developed to enable complete end-stage or real-time PCR assays to
Biofortuna Ltd, a UK-based diagnostics company offering molecular diagnostic products and contract manufacturing services, has raised £1.6M in its latest funding round. The new funding –supported by current investor Foresight VCTs and members of the senior management team – will allow the company to take its ReadyPlex™ rapid blood group genotyping assays into clinical trials and commercialisation, as well as